

POSTER PRESENTATIONS

DAY 2; SATURDAY, 7 DECEMBER 2019 | 07:40 - 08:40

Faculty: Muhammed Abuzokouk (PP-01 / PP-10)

- PP - 01** Updosing omalizumab in chronic spontaneous urticaria: A case series
Murat Türk, Insu Yılmaz
- PP - 02** Clinico-demographic study of chronic urticaria from a tertiary care center in North India - A 5-year retrospective analysis
Sendhil Muthu Kumaran, Vishal Thakur, Manju Daroach, Davinder Parsad
- PP - 03** Experience with omalizumab for the treatment of chronic spontaneous urticaria in a tertiary center
Ayda Acar, Bengü Gerçeker Türk, İlgem Ertam Sağduyu, Can Ceylan, Günseli Öztürk, İdil Ünal
- PP - 04** Effect of omalizumab treatment on disease activity in chronic spontaneous/idiopathic urticaria: Results from XTEND-CIU, a longitudinal perspective
Marcus Maurer, Thomas R. Murphy, Michael Holden, Ahmar Iqbal, Bongin Yoo, Thomas B. Casale
- PP - 05** Effective treatment of refractory chronic spontaneous urticaria with omalizumab and add-on ciclosporin: From guideline to real life practice
Suphattra Trakanwittayarak, Rungsima Kiratiwongwan, Papapit Tuchinda, Leena Chularojanamontri, Kanokvalai Kulthanan
- PP - 06** Experience with omalizumab in a cohort of patients with chronic spontaneous urticaria: Clinical outcomes and drug survival analysis
Ferran Olmos Alpiste, Álvaro March Rodríguez, Gustavo Deza, Xavier Duran, Ramon M^a Pujol Vallverdú, Ana María Giménez Arnau
- PP - 07** Evaluation of serum substance P level in chronic urticaria and correlation with disease severity
Maryam Khoshkhui, Javad Fadaee, Farahzad Jabbari Azad, Reza Farid Hosseini
- PP - 08** A significant association between Taq1 gene polymorphism in vitamin D receptor and chronic urticaria in the city of Mashhad, Northeast of Iran
Maryam Khoshkhui, Mojgan Mohammadi
- PP - 09** Clinical characteristics and management of inducible chronic urticaria in a pediatric cohort
Bruce Thomas Miles, Sofianne Gabrielli, Elena Netchiporouk, Sharon Baum, Greenberger Shoshana, Petra Straubach Renz, Moshe Ben Shoshan
- PP - 10** Ligelizumab is well tolerated and exhibits a safety profile similar to omalizumab and placebo in patients with chronic spontaneous urticaria
Sussman Gordon, Marcus Maurer, Ana Giménez Arnau, Eva Hua, Thomas Severin, Reinhold Janocha

POSTER PRESENTATIONS

DAY 2; SATURDAY, 7 DECEMBER 2019 | 07:40 - 08:40

Faculty: *Maryam Ali Al-Nesf Al-Mansouri (PP-11 / PP-20)*

- PP - 11** Ligelizumab retreatment is highly effective in patients with chronic spontaneous urticaria
Marcus Maurer, Ana Giménez Arnau, Gordon Sussman, Eva Hua, Thomas Severin, Reinhold Janocha
- PP - 12** Ligelizumab achieves sustained control of chronic spontaneous urticaria symptoms of hives, itch and angioedema: 1-year treatment results
Jonathan Bernstein, Diane Baker, Marcus Maurer, Ana Giménez Arnau, Gordon Sussman, Avantika Barve, Eva Hua, Thomas Severin, Reinhold Janocha
- PP - 13** Impact of omalizumab treatment withdrawal after 24 and 48 weeks in patients with chronic idiopathic urticaria: results from the XTEND-CIU study
Allen Kaplan, Thomas R. Murphy, Michael Holden, Ahmar Iqbal, Bongin Yoo, Jonathan A. Bernstein
- PP - 14** More patients treated with ligelizumab are angioedema-free compared with omalizumab: Results of a phase 2b clinical trial
Ana Giménez Arnau, Gordon Sussman, Marcus Maurer, Eva Hua, Kenneth Kobayashi, Reinhold Janocha, Thomas Severin, Maria Magdalena Balp
- PP - 15** Ligelizumab reduces rescue medication use in patients with chronic spontaneous urticaria: Phase 2b study results
Karl Sitz, Weily Soong, Bobby Lanier, Kenneth Kobayashi, Avantika Barve, Eva Hua, Reinhold Janocha, Thomas Severin
- PP - 16** Dose-finding phase 2 study to evaluate efficacy and safety of the novel BTK inhibitor LOU064 in patients with CSU inadequately controlled by H1-antihistamines
Julian Störöm, Karine Lheritier, Sophie Hugot, Peter End, Bruno Bieth, Bruno Cenni, Martin Kaul, Ana Gimenez Arnau, Marcus Maurer, Thomas Severin
- PP - 17** Re-treatment with ligelizumab achieves high rates of completely- and well-controlled symptoms in chronic spontaneous urticaria
Martin Metz, Diane Baker, Chia Yu Chu, Inna Danilycheva, Eva Hua, Kenneth Kobayashi, Reinhold Janocha, Thomas Severin
- PP - 18** Results from the phase 2b study demonstrate that ligelizumab achieves sustained control of CSU symptoms during treatment-free follow-up
Sinisa Savic, Gordon Sussman, Jonathan Bernstein, Jacques Hebert, Constance Katelaris, Eva Hua, Avantika Barve, Thomas Severin, Reinhold Janocha
- PP - 19** Study design and rationale of a phase 2b dose-finding study of ligelizumab (QGE031) in adolescent patients with chronic spontaneous urticaria
Anton Drollmann, Miriam Porter, Naoka Kataoka, Stephan Koehne Voss, Marcus Maurer, Petra Staubach, Moshe Ben Shoshan, Bulent Sekerel, Reinhold Janocha, Thomas Severin
- PP - 20** Basophil high-affinity IgE receptor expression as a biomarker in Chronic Urticaria, a standardized assessment recommendation
Clara Ribas Llauradó, Gustavo Deza, Dulce Soto, Ramon Pujol, Ramon Gimeno, Ana Gimenez Arnau

POSTER PRESENTATIONS

DAY 2; SATURDAY, 7 DECEMBER 2019 | 07:40 - 08:40

Faculty: Kurtuluş Aksu (PP-21 / PP-30)

- PP - 21** Differences in clinical and laboratory parameters and treatment response rates between autologous serum test positive and negative patients
Sinem Ayşe Örnek, Onur Gündoğdu, Pelin Kuteyla Can, Emek Kocatürk
- PP - 22** Successful treatment of refractory symptomatic dermographism and cholinergic urticaria in 8 years old girl with omalizumab
Bidzina Kulumbegov, Maia Gotua
- PP - 23** Predictors of response to treatment in chronic spontaneous urticaria – results of a systematic review
Pavel Kolkhir, Jie Shen Fok, Martin K Church, Marcus Maurer
- PP - 24** Management of Chronic Spontaneous Urticaria during pregnancy and in woman who plan to conceive while on ongoing treatment
Michael Rudenko, Hilary Longhurst, Lucia Pozo Garcia, Katya Burova, Raisa Meshkova, Roman Kozlov, Alexander Marsland
- PP - 25** Events during the three months immediately preceding onset of chronic urticaria: a retrospective questionnaire study
Sedra Ali, Misbah Noshela Ghazanfar, Jesper Grønlund Holm, Simon Francis Thomsen
- PP - 26** In chronic spontaneous urticaria, basophil testing for autoreactivity predicts heterologous mast cell responses to autologous serum, {in vitro} and {in situ}
Katrine Baumann, João Marcelino, Jörg Scheffel, Célia Costa, Maria Conceição Pereira Santos, Marcus Maurer, Per Stahl Skov
- PP - 27** Analysis of anti-IL-24-IgE in chronic spontaneous urticaria
Yikui Xiang, Sabine Altrichter, Jörg Scheffel, Marcus Maurer
- PP - 28** Anti-thyroid antibodies as biomarkers for disease duration in chronic spontaneous urticaria
Larissa S Brandao, Patricia Guerzet Ayres Bastos, Barbara Martins De Aquino, Dirceu Sole, Ines C Camelo Nunes, Luis Felipe Ensina
- PP - 29** Autoreactivity by ASST, BAT and BHRA correlates with more severe CSU
João Marcelino, Célia Costa, Per S Skov, Katrine Baumann, Maria C Pereira Santos, Marcus Maurer
- PP - 30** Autoreactivity in CSU is associated with angioedema, nocturnal symptoms, long lasting wheals, thyroid autoantibodies, lower total serum IgE and the need for omalizumab therapy
João Marcelino, Célia Costa, Per S Skov, Per S Skov, Katrine Baumann, Maria C Pereira Santos, Marcus Maurer

POSTER PRESENTATIONS

DAY 2; SATURDAY, 7 DECEMBER 2019 | 07:40 - 08:40

Faculty: Kemal Özyurt (PP-31 / PP-40)

- PP - 31** In patients with chronic spontaneous urticaria, positive autologous serum tests are only weakly correlated with positive basophil tests
João Marcelino, Célia Costa, Per S Skov, Katrine Baumann, Maria C Pereira Santos, Marcus Maurer
- PP - 32** High dose omalizumab in patients with chronic spontaneous urticaria
Mehran Alizadeh Aghdam, Fenne van den Broek, Feiko Rijken, André C Knulst, Heike Röckmann
- PP - 33** Effects and markers of response of omalizumab in normocomplementemic urticarial vasculitis
Yudi Chen, Karoline Krause, Ping Tu, Zuotao Zhao, Marcus Maurer
- PP - 34** Mast cell chymase cleaves C1-Inhibitor and leads to Angioedema formation
Carolina Elisa Vera Ayala, Marcus Maurer, Jörg Scheffel
- PP - 35** Evaluation of Factors Affecting Drug Survival and Treatment Responses of The Patients with Chronic Urticaria on Omalizumab Treatment Omalizumab
Eda Haşal, Emel Bülbül Başkan, Serkan Yazıcı, Kenan Aydoğan, Hayriye Sarıcaoğlu
- PP - 36** Possible involvement of high histamine concentration in sweat in association with type-I-hypersensitivity against sweat in patients with cholinergic urticaria
Shunsuke Takahagi, Mayumi Okamoto, Kaori Ishii, Michihiro Hide
- PP - 37** Safety and Efficacy Data of AK002, an Anti-Siglec-8 Monoclonal Antibody, in Patients (pts) with Indolent Systemic Mastocytosis (ISM): Results from a First-in-Human, Open-label Phase 1 Study
Frank Siebenhaar, Hanna Bonnekoh, Tomasz Hawro, Marlena O. Hawro, Edward G. Michaelis, Henrik S. Rasmussen, Bhupinder Singh, Andrea M. Kantor, Alan T. Chang, Marcus Maurer
- PP - 38** Chronic spontaneous urticaria: different patterns of response to treatment are not necessarily only related to different patients, but also to different periods of the disease in the same patient
Isabel Ogueta Canales, Ana María Giménez Arnau
- PP - 39** Cold urticaria and other cold-induced reactions - Comprehensive Evaluation: The UCARE project COLD-CE
Dorothea Terhorst Molawi, Mojca Bizjak, Mitja Kosnik, Kanokvalai Kulthanan, Raisa Meshkova, Simon Francis Thomsen, Marcus Maurer
- PP - 40** Eosinopenia is associated with type IIb autoimmune chronic spontaneous urticaria and poor response to treatment
Pavel Kolkhir, Martin K Church, Sabine Altrichter, Per Stahl Skov, Tomasz Hawro, Stefan Frischbuter, Martin Metz, Marcus Maurer

POSTER PRESENTATIONS

DAY 2; SATURDAY, 7 DECEMBER 2019 | 07:40 - 08:40

Faculty: Roberto Criado (PP-41 / PP-50)

- PP - 41** Clinical and laboratory features associated with poor control after treatment with omalizumab: A preliminary study
Nobuko Sagawa, Naoko Inomata, Saki Takahashi, Rie Fukuzawa, Masako Tanaka, Aiko Takano, Yukitoshi Takahashi, Michiko Aihara
- PP - 42** A case of chronic spontaneous urticaria, which masked concomitant hereditary angioedema: A family study
Maia Gotua, Bidzina Kulumbegov, Maia Rukhadze, Nino Lomidze, Madona Devidze, Nana Dolidze
- PP - 43** Acetylcholine-induced whealing in cholinergic urticaria - what does it tell us?
Sabine Altrichter, Yiyu Wang, Pia Schumacher, Ola Alraboni, Marcus Maurer
- PP - 44** Clinical activity of AK002, an anti-Siglec-8 antibody, in multiple forms of uncontrolled chronic urticaria
Sabine Altrichter, Petra Staubach, Malika Pasha, Henrik S. Rasmussen, Bhupinder Singh, Alan T. Chang, Amol Kamboj, Jonathan A. Bernstein, Frank Siebenhaar, Marcus Maurer
- PP - 45** Development of the Angioedema Control Test (AECT) - a patient reported outcome measure that assesses disease control in patients with recurrent angioedema
Karsten Weller, Tamara Donoso, Markus Magerl, Emel Aygören Pürsün, Petra Staubach, Inmaculada Martinez Sagner, Tomasz Hawro, Frank Siebenhaar, Martin Metz, Torsten Zuberbier, Denise Freier, Marcus Maurer
- PP - 46** Chronic pruritus in skin diseases is more common and more severe than we thought
Tomasz Hawro, Katarzyna Przybyłowicz, Max Spindler, Marlena Hawro, Michał Steć, Sabine Altrichter, Karsten Weller, Markus Magerl, Ezzat Alarbed, Ola Alraboni, Marcus Maurer, Martin Metz
- PP - 47** Severe thrombocytopenic purpura during omalizumab treatment for chronic spontaneous urticaria
Leila Borges Neves, Jose Carlison Oliveira, Tarso Bomfim Barbosa, Joanemile Pacheco De Figueiredo, Regis Albuquerque Campos
- PP - 48** GI-301: A novel long-acting IgETrap-Fc fusion protein for IgE-mediated allergic diseases
Kyungwha Lee, Bo Gie Yang, Jiyoung Kim, Sungman Oh, Su Youn Nam, Myoung Ho Jang
- PP - 49** Awareness of family physicians towards double dosing of antihistamines
Ruchita Bharat Hasija, Kiran Godse
- PP - 50** UVERSICU: Urticarial vasculitis versus chronic spontaneous urticaria - Natural history, disease course and response to treatment – preliminary data from the UCARE project
Hanna Bonnekoh, Marcia Lima Pedrosa, Viktoria Puhl, Tomasz Hawro, Marcus Maurer, Karoline Krause

POSTER PRESENTATIONS

DAY 2; SATURDAY, 7 DECEMBER 2019 | 07:40 - 08:40

Faculty: *Raisa Meshkova (PP-51 / PP-60)*

- PP - 51** Can histopathology distinguish chronic spontaneous urticaria from urticarial vasculitis?
Mariana Batista, Francisca Moragdo, José C Cardoso, Oscar Tellechea, Margarida Goncalo
- PP - 52** Impact of Chronic Urticaria on spiritual well-being and quality of life
Sergio Duarte Dortas Junior, Guilherme Gomes Azizi, Rafael Neves Moret, Solange Oliveira Rodrigues Valle
- PP - 53** Beyond the limit of cold urticaria: Autologous plasma skin test in a case series
Zafer Türkoğlu, Yavuz Tezcan, Filiz Topaloğlu Demir, Tuğba Atcı, Ceyda Çaytemel
- PP - 54** Evaluation of potential risk factors for relapse after omalizumab cessation in recalcitrant chronic urticaria
Semra Demir, Nida Öztop, Özdemir Can Tüzer, Şengül Beyaz, Ozan Osman Yegit, Ali Can, Pelin Karadağ, Deniz Eyice Karabacak, Bahauddin Çolakoğlu, Suna Büyüköztürk, Aslı Gelincik
- PP - 55** Serum galectin-1, galectin-3 and galectin-9 are bystander molecules for chronic spontaneous urticaria
Zheng Lin, Shi Zhen Rui, Tan Guo Zhen, Wang Liangchun
- PP - 56** Concomitant presence of hereditary angioedema and chronic spontaneous urticaria in two consecutive generations of a family
Özdemir Can Tüzer, Semra Demir, Suna Büyüköztürk, Bahauddin Çolakoğlu, Aslı Gelincik
- PP - 57** Low IgA and IgE levels in patients with chronic spontaneous urticaria are associated with autoimmune phenomena
Merle Sauer, Jörg Scheffel, Stefan Frischbutter, Frank Siebenhaar, Sabine Altrichter, Marcus Maurer, Martin Metz, Karoline Krause
- PP - 58** Uncommon cause of recalcitrant chronic urticaria: Latent syphilis
Özdemir Can Tüzer, Semra Demir, Seniha Başaran, Suna Büyüköztürk, Bahauddin Çolakoğlu, Aslı Gelincik
- PP - 59** Prevalence of urticaria in the Greek population: The effect of gender and time
Anna Tagka, Michael Makris, Alexandros Stratigos, George I Lambrou, Evangelia Nakou, Electra Nicolaidou, Simeon Kedikoglou, Argyro Chatziioannou, Alexandra Katsarou
- PP - 60** A comparative study of skin writometer and friction test dermatographometer in symptomatic dermatographism
Ashwini Satyanarayan Kandikatla, Kiran Godse

POSTER PRESENTATIONS

DAY 2; SATURDAY, 7 DECEMBER 2019 | 07:40 - 08:40

Faculty: Naoka Inomata (PP-61 / PP-70)

- PP - 61** The efficacy of omalizumab in chronic spontaneous urticaria
Meltem Türkmen, Sinan Doğan
- PP - 62** Real-life efficacy predictors of Omalizumab treatment in patients with chronic urticaria
Marisa Paulino, Célia Costa, João Marcelino, Manuel Pereira Barbosa
- PP - 63** Long term omalizumab treatment in chronic spontaneous urticaria: Efficacy and safety in patients over a period of three years
Sinem Örneş, Emek Kocatürk
- PP - 64** Relationship between serum C-C chemokine ligand 2 (CCL2) levels and severity of chronic spontaneous urticaria in children
Esra Yücel, Deniz Özçeker
- PP - 65** Analysis of Omalizumab Treatment Chronic Spontaneous Urticariae Patients: Real life study from single center in Istanbul
Zeynep Ferhan Özşeker, Gülsüm Karakaş
- PP - 66** Infrared thermography; a new diagnostic method in heat contact urticaria: Case report
Zafer Türkoğlu, Filiz Topaloğlu Demir, Tuğba Özkök Akbulut, Yavuz Tezcan, Ceyda Çaytemel
- PP - 67** Soluble FcεRI is a potential biomarker for poor therapeutic response to omalizumab in patients with chronic spontaneous urticaria
Sherezade Moñino Romero, Pavel Kolkhir, Zsolt Szépfalusi, Marcus Maurer, Sabine Altrichter
- PP - 68** Omalizumab treatment in cholinergic urticaria patients
Thomas Buters, Martijn Van Doorn
- PP - 69** No difference in cold urticaria between female and male
Raisa Yakovlevna Meshkova, Nataliya Vasilevna Kovrigina, Svetlana Anatolevna Aksenova, Alexander Vladimirovich Vitshuk
- PP - 70** No difference in chronic spontaneous urticaria between patients with angioedema and without angioedema
Raisa Yakovlevna Meshkova, Alexander Vladimirovich Vitshuk, Nataliya Vasilevna Kovrigina, Svetlana Anatolevna Aksenova